Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MC3R agonist
- Development stage
- Preclinical
- Lead developer
- Courage Therapeutics
- Modality
- Modified Peptides → Peptides, Small Molecules
- Administration
- Intraperitoneal, Intracerebroventricular, Intrathecal, Ophthalmic, Oral, Topical, Transdermal, Intranasal, Inhalation, Buccal, Rectal, Vaginal, Intravenous, Subcutaneous, Intratumoral
01
Overview
Courage Therapeutics is developing melanocortin-3 receptor (MC3R) agonists as peptide and small molecule therapeutics for the treatment of cachexia and other diseases of wasting. The MC3R program focuses on stimulating food intake by targeting neural circuits in the central melanocortin system. Based on research from founder Dr. Roger Cone at the University of Michigan, these agonists are designed to drive increased feeding behavior. The program is currently in lead optimization, with potential applications in cachexia, anorexia nervosa, sarcopenia, and geriatric anorexia.
- Other names
- melanocortin 3 receptor agonistmelanocortin3 receptor agonistmelanocortin-3 receptor agonist
02
Targets
MC3R (Melanocortin Receptor Type 3)
Beyond the preview
Go deeper on MC3R agonist.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MC3R agonist.